First-line vascular endothelial growth factor targeted therapy in renal cell carcinoma: priming the tumor microenvironment for immunotherapy

References

• American Cancer Society. Kidney Cancer. 2016. Available at: https://www.cancer.org/cancer/kidney-cancer.html [Last accessed 10 October 2017]
   Google Scholar
• Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 1993;260:1317-20
   PubMed Web of Science ®Google Scholar
• Jonasch E, Gao J, Rathmell WK. Renal cell carcinoma. BMJ 2014;349:g4797
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidlines in Oncology. Kidney Cancer, version 1. 2018. 2017. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf [Last accessed 10 October 2017]
   Google Scholar
• Choueiri TK, Motzer RJ. The right drug for the right patient: navigating systemic therapy options in metastatic renal cell carcinoma and future directions. J Natl Compr Canc Netw 2015;13:1168-1170
   PubMed Web of Science ®Google Scholar
• Weinstock M, McDermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2015;7:365-77
   PubMed Web of Science ®Google Scholar
• Milella M, Felici A. Biology of metastatic renal cell carcinoma. J Cancer 2011;2:369-73
   PubMed Web of Science ®Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v58-68
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Albiges L, Bensalah K, et al. Renal Cell Carcinoma. 2017. Available at: http://uroweb.org/guideline/renal-cell-carcinoma/ [Last accessed 10 October 2017]
   Google Scholar
• Harshman LC, Drake CG, Choueiri TK. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol Res 2014;2:1132-41
   PubMed Web of Science ®Google Scholar
• Voron T, Colussi O, Marcheteau E, et al. VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J Exp Med 2015;212:139-48
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013;39:1-10
   PubMed Web of Science ®Google Scholar
• Bedke J, Kruck S, Gakis G, et al. Checkpoint modulation – a new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother 2015;11:1201-8
   PubMed Web of Science ®Google Scholar
• Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. Semin Cancer Biol 2015;35:S185-S98
   PubMed Web of Science ®Google Scholar
• Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10:6342-6S
   PubMed Web of Science ®Google Scholar
• Raman R, Vaena D. Immunotherapy in metastatic renal cell carcinoma: a comprehensive review. Biomed Res Int 2015:367354. doi: 10.1155/2015/367354
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64
   PubMed Web of Science ®Google Scholar
• Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207-12
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847-56
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Nole F, Verri E, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target Oncol 2016;11:143-8
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13
   PubMed Web of Science ®Google Scholar
• McDermott D, Atkins MB, Motzer RJ, et al. A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). J Clin Oncol 2017;35:431
   Web of Science ®Google Scholar
• Opdivo [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, 2017
   Google Scholar
• Yervoy [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company, 2017
   Google Scholar
• Oudard S, Benhaouda N, Escudier B, et al. Decrease of pro-angiogenic monocytes predicts clinical response to anti-angiogenic treatment in patients with metastatic renal cell carcinoma. Eur J Cancer 2015;51:S89-S90
   Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9
   PubMed Web of Science ®Google Scholar
• Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381-5
   PubMed Web of Science ®Google Scholar
• Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004;101:17174-9
   PubMed Web of Science ®Google Scholar
• Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007;13:1757-61
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008;14:6674-82
   PubMed Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57
   PubMed Web of Science ®Google Scholar
• Alfaro C, Suarez N, Gonzalez A, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009;100:1111-19
   PubMed Web of Science ®Google Scholar
• Liu XD, Hoang A, Zhou L, et al. Resistance to antiangiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res 2015;3:1017-29
   PubMed Web of Science ®Google Scholar
• Adotevi O, Pere H, Ravel P, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010;33:991-8
   PubMed Web of Science ®Google Scholar
• Stewart GD, De Santis M, Escudier B, et al. Immunotherapy for renal cancer: sequencing and combinations. Eur Urol Focus 2016;2:582-8
   PubMedGoogle Scholar
• Shablak A, Gilham DE, Hawkins RE, Elkord E. In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells. Expert Opin Pharmacother 2014;15:1489-99
   PubMed Web of Science ®Google Scholar
• Stehle F, Schulz K, Fahldieck C, et al. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem 2013;288:16334-47
   PubMed Web of Science ®Google Scholar
• Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Imarisio I, et al. Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J Cancer 2011;2:333-8
   PubMed Web of Science ®Google Scholar
• Nuti M, Zizzari I, Napoletano C, et al. Immunomodulatory effects of tyrosine kinase inhibitors (TKIs) in renal cell carcinoma (RCC) patients. J Clin Oncol 2017;35:e14506
   Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31
   PubMed Web of Science ®Google Scholar
• Escudier B, Sharma P, McDermott DF, et al. CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma. Eur Urol 2017;72:962-971
   PubMed Web of Science ®Google Scholar
• Lakshmi Narendra B, Eshvendar Reddy K, Shantikumar S, Ramakrishna S. Immune system: a double-edged sword in cancer. Inflamm Res 2013;62:823-34
   PubMed Web of Science ®Google Scholar
• Bose A, Taylor JL, Alber S, et al. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int J Cancer 2011;129:2158-70
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ishida T, Nadaf S, et al. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5:2963-70
   PubMed Web of Science ®Google Scholar
• Shrimali RK, Yu Z, Theoret MR, et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. Cancer Res 2010;70:6171-80
   PubMed Web of Science ®Google Scholar
• Amin A, Plimack ER, Infante JR, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2014;32:abstract 5010
   Web of Science ®Google Scholar
• Curran MA, Montalavo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010;107:4275-80
   PubMed Web of Science ®Google Scholar
• Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 Study. J Clin Oncol 2017: published online, doi:10.1200/JCO.2016.72.1985
   PubMed Web of Science ®Google Scholar
• Choueri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol 2016;35:591-7
   PubMed Web of Science ®Google Scholar